×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Prostate Cancer

Feature Video
Receiving a diagnosis of prostate cancer can be frightening and confusing. Understanding the details of your specific cancer and how they relate to your prognosis and treatment planning is an important first step toward shared decision-making between you and your physicians. In these CURE Connections programs you will learn the meaning of the PSA test, prostate cancer staging and grading, and how these factors are used to determine which treatment approach is right for you. Management of prostate cancer related symptoms, available treatments, and how to deal with side effects are also discussed. In addition, you will hear from patients and caregivers about their personal experiences with prostate cancer.
Silas Inman
The Food and Drug Administration (FDA) approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC), according to Sun Pharma, the company commercializing the treatment.
Tony Berberabe, MPH
The group came together to discuss gaps in knowledge concerning the prostate cancer journey, including nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic disease.
Kristie L. Kahl
As part of the Prostate Cancer Foundation’s first annual campaign, Kristen Bell selected two winners because of their ‘candor and honesty’ to be honored.
Kristie L. Kahl
After his own journey with prostate cancer, radio and TV personality Ed Randall used his extensive connections throughout professional sports to spread awareness about prostate cancer through his nonprofit organization Fans for the Cure.
Brielle Urciuoli
Women felt that they could not show emotions of fear or vulnerability in front of their husbands or children.
Kristie L. Kahl
What do Bill Nye the Science Guy, fashion designer Michael Kors and one very special prostate cancer advocate all have in common? Blue jackets, a runway and the ultimate goal of raising awareness for prostate cancer.
Jason Harris
The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.
Kristie L. Kahl
With just one catwalk, the Prostate Cancer Foundation brought together celebrities, fashion designers and a special patient advocate to raise awareness for prostate cancer.
Jason M. Broderick
The Food and Drug Administration (FDA) approved Erleada (apalutamide) for the treatment of patients who have nonmetastatic castration-resistant prostate cancer (CRPC). The drug is now the first FDA-approved treatment in this setting.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable